Quantitative Effects of Palivizumab and Donor-Derived T Cells on Chronic Respiratory Syncytial Virus Infection, Lung Disease, and Fusion Glycoprotein Amino Acid Sequences in a Patient Before and After Bone Marrow Transplantation

A patient with respiratory syncytial virus (RSV) infection and severe combined immunodeficiency was studied during a 3-month period of bone marrow transplantation and palivizumab infusion. No RSV isolates with palivizumab escape mutations were identified. Donor lymphocytes, including CD8 cells, appe...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2004-07, Vol.39 (2), p.e17-e20
Main Authors: El Saleeby, C. M., Suzich, J., Conley, M. E., DeVincenzo, J. P.
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Antibodies, Monoclonal - metabolism
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Bone Marrow Transplantation - immunology
Humans
Immunoglobulins, Intravenous - therapeutic use
Immunosuppressive Agents - therapeutic use
Infant
Lymphocyte Count
Male
Palivizumab
Pneumonia, Viral - immunology
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - immunology
Respiratory Syncytial Virus Infections - therapy
Respiratory Syncytial Virus Infections - virology
Respiratory Syncytial Virus, Human - immunology
Severe Combined Immunodeficiency - complications
Severe Combined Immunodeficiency - therapy
T-Lymphocytes - physiology
Viral Fusion Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A patient with respiratory syncytial virus (RSV) infection and severe combined immunodeficiency was studied during a 3-month period of bone marrow transplantation and palivizumab infusion. No RSV isolates with palivizumab escape mutations were identified. Donor lymphocytes, including CD8 cells, appeared to markedly reduce the RSV load but increased the pulmonary symptoms. Immunosuppressive therapy ameliorated lung disease but allowed the RSV load to rebound.
ISSN:1058-4838
1537-6591
DOI:10.1086/421779